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Background. Perception remains that brachytherapy-based regimens are inappropriate for patients having increased risk of
extracapsular extension (ECE). Methods. 321 consecutive intermediate and high-risk disease patients were treated between 1/92
and 2/97 by one author (M. Dattoli) and stratiﬁed by NCCN guidelines. 157 had intermediate-risk; 164 had high-risk disease.
All were treated using the combination EBRT/brachytherapy ± hormones. Biochemical failure was deﬁned using PSA > 0.2a n d
nadir +2 at last followup. Nonfailing patients followup was median 10.5 years. Both biochemical data and original biopsy slides
were independently rereviewed at an outside institution. Results. Overall actuarial freedom from biochemical progression at 16
years was 82% (89% intermediate, 74% high-risk) with failure predictors: Gleason score (P = .01) and PSA (P = .03). Hormonal
therapy did not aﬀect failure rates (P = .14). Conclusion. This study helps to strengthen the rationale for brachytherapy-based
regimens as being both durable and desirable treatment options for such patients. Prospective studies are justiﬁed to conﬁrm these
positive results.
1.Introduction
Whereas modern prostate brachytherapy using transrectal
ultrasound and sophisticated treatment planning was met
with much skepticism when introduced in the 1980s,
favorable longer-term outcomes are fueling its widespread
adoption [1, 2]. Brachytherapy has since enjoyed growing
acceptance for treatment of low risk patients, that is, those
with a PSA less than 10ng/mL, Gleason score 6, and low
volume cancer in the biopsy core specimens [3, 4]. However,
there is a continued controversy regarding its use for patients
at higher risk of extracapsular cancer extension (ECE) [5–7].
IthasbeenwellestablishedthatpatientswithhigherPSAand
Gleason scores are at higher risk of ECE, with the likelihood
of ECE being approximately 50% in patients with a PSA
o v e r1 0n g / m Lo raG l e a s o ns c o r eo f7o rh i g h e r[ 8]. It has
been assumed that external beam radiation alone should be
the basis of treatment for such patients, the logic being that
EBRT would provide better coverage of ECE [9]. Some early
reports appeared to support the concept of brachytherapy
being ill-advised for these patients [10, 11].
While it may seem superﬁcially logical to avoid
brachytherapy for patients at higher risk of ECE, studies
regarding the radial extent of ECE have cast doubt on
such a policy. Most importantly, ECE is typically limited
to 3–5mm, and can be treated with peripherally loaded
implants that provide high doses to the periprostatic tissues
[12]. Although some early reports showed poor results2 Journal of Oncology
using brachytherapy in patients having higher risk features,
there is a growing number of reports showing favorable
results with brachytherapy-based treatment for patients with
a high likelihood of ECE, especially when combined with
supplemental EBRT [6, 7, 13–16].
One criticism of most brachytherapy outcomes reports
has been the lack of long-term followup, with the possibility
of prematurely concluding that cancer has been eradicated
in high-risk patients. Reports to date have generally been
limitedtoamedianfollowupof5years.Accordingly,wehave
updated our ongoing analysis of external beam radiation
(EBRT) plus brachytherapy using Pd-103.
2.MaterialsandMethods
Three hundred twenty-one consecutive patients were treated
between January 1992 and February 1997 by the primary
author, and M. Dattoli.
Patients were classiﬁed into prognostic risk groups as
deﬁned by the National Comprehensive Cancer Network
guidelines (intermediate risk: T2B–T2C or Gleason 7, or PSA
10–20; high risk: T3A or Gleason 8–10, or PSA above 20).
The original biopsy slides of the 321 patients were
retrieved and rereviewed by outside pathologists (L. True
or D. Bostwick) to independently verify the patients’ tumor
grade with 30% identiﬁed to be undergraded and 6% being
overgraded.Allbiochemicaldatawerealsoindependentlyre-
reviewed at the University of Washington (K.W.). Only one
patient had a staging pelvic lymphadenectomy. Postimplant
saturation biopsies were only performed for patients having
a rising PSA. Enzymatic prostatic acid phosphatase (PAP)
was analyzed independent of risk stratiﬁcation grouping as
the primary author (M. Dattoli) has previously identiﬁed
the importance of this marker as an adverse prognosticator
[6, 17, 18]. PAP was determined by the method of Roy
and colleagues, with values up to 2.5U considered normal
[17, 18]. All patients who met intermediate or high-risk
criteria underwent combination external beam irradiation
plus Pd-103 brachytherapy, with the only exception being
that of patients having enlarged gland sizes in excess of
70cm3 and/or excessive TURP defects. Sixty patients had
pretreatment TURPS and 30 patients had pretreatment
TUIPS.
Patients received a median 4140cGy 3-dimensional con-
formal radiotherapy (3D-CRT) over 4.5 weeks to the pelvic
ﬁeldcoveringtheprostate,seminalvesicles,andlymphnodes
up to the common iliacs (dose range: 39–60Gy, 180cGy/Fx),
followed 2 to 4 weeks later by a Pd-103 boost, using
transrectal ultrasound and ﬂuoroscopic guidance. Only free
seeds were utilized and all patients underwent pretreatment
and intraoperative TRUS planning, while all patients under-
went postimplant CT imaging for dosimetric analysis and
source counting on postoperative Day 1. Extraprostatic seed
placementwasroutinelyperformedasdescribedbyDattoliet
al.[19]TheprescribedminimumPd-103dosetotheprostate
was 80–90Gy (pre-NIST-99). A median of 104.3mCi Pd-
103 was implanted with a range of 48–144mCi. The median
source strength was 1.4mCi (range:1.0–1.6mCi/source).
Generous brachytherapy margins were utilized; the clinical
target volume extended 0.5–1.0cm anterolaterally to the
TRUS prostate margin (no posterior margin was added
beyond the TRUS delineated posterior border). Patients
having 3 or more risk features (PSA, Gleason score, Clinical
Stage, elevated PAP) were encouraged to receive hormonal
agents and 143 patients received hormones in neoadjuvant
or adjuvant fashion, median duration 4 months (maximum
6 months). Patients were planned to be followed at 6 and
12 months for the ﬁrst 5 years, and then every 12 months
thereafter. At the time of their follow-up visit, data recorded
included their IPSS and rectal functioning assessment score
(R-FAS). Those patients who did not appear for their
scheduled follow-ups (beyond 12 months, 20 patients) were
mailed the IPSS and R-FAS. Ultimately, all living patients in
this study were evaluated by personal visits with the longest
time lapse being 18 months. Eighteen patients experiencing
Grade II proctitis beyond 6 months were recommended
to undergo colonoscopy to rule out ﬁstulas or ulceration,
revealing only erythematous changes and/or prominent
internal hemorrhoids.
Freedom from biochemical failure was deﬁned using a
serum PSA < 0 . 2 n g / m L( a to ra f t e rn a d i r )a tl a s tf o l l o w -
up. The Phoenix deﬁnition of PSA nadir +2 was also
used. Using PSA < 0.2ng/mL for disease failure allows for
reasonable comparison to radical prostatectomy series, as
well as recent brachytherapy studies while PSA nadir +2
allows for comparison to contemporary IMRT series [20–
22].
Patients were censored at last follow-up if their serum
PSA was still decreasing (3 patients). Patients whose PSA
nadired > 0.2ng/mL or who exceeded the PSA nadir +2
deﬁnition were scored as failures at the time at which their
PSA progressed. Both deﬁnitions (PSA < 0.2ng/mL and PSA
nadir +2) needed to be satisﬁed to be considered free from
biochemical failure. The follow-up period for nonfailing
patients was 16 years (median 10.5 years). Biochemical
failurecurveswerecalculatedbythemethodofKaplan-Meier
and freedom from biochemical failure was deﬁned as both a
PSA<0.2,orariseinPSAthatdoesnotexceedthePSAnadir
+2 deﬁnition. Diﬀerences between groups were determined
by log-rank method.
Individual NCCN risk factors (Clinical Stage, Gleason
score, PSA) were also subject to multivariate Cox pro-
portional hazards analysis considering each factor as a
continuous variable. Treatment with or without hormones
was subject to the methods of Kaplan-Meier. Since this
primary author (M. Dattoli) has previously identiﬁed PAP
as a signiﬁcant adverse prognosticator, this risk feature was
also subjected to the same multivariate analysis.
3. Results
157 patients had intermediate risk disease and 164 had high
risk disease. This included 218 patients having Gleason Score
7 or greater with 52 patients having Gleason 8–10; 203
patients having PSA > 20; 130 patients had clinical stage T3;
158 patients had clinical stage T2c; 20 patients had clinicalJournal of Oncology 3
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Figure 1: Combined freedom from biochemical progression (using
PSA nadir +2, PSA < 0.2 at last follow-up) when evaluated for
all 321 patients treated with PD-103 plus median 41Gy beam
radiation. (No signiﬁcant variance was identiﬁed when plotting
graphs using the two deﬁnitions.) (univariate analysis).
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Figure 2: Freedom from biochemical progression (PSA <
0.2ng/mL, nadir +2) stratiﬁed per Gleason score (multivariate
analysis).
Table 1: Disease characteristics for 321 patients.
Characteristics Patients (n)
Clinical Stage:
T3 130
T2c 158
T2b 20
T2a 10
T1c 3
Gleason:
7 218
83 2
9-10 18
PSA:
0–10 141
10–20 116
>20 64
stageT2b; and 10 patients had clinical stage T2a and 3 patients
had clinical stage T1c (Table 1). Seventy-nine patients had
abnormally elevated PAP’s. Patient ages ranged from 43 to
88 years (median: 66 years).
The overall actuarial freedom from biochemical pro-
gression at 16 years is 82%, with 222 patients followed
Table 2: Predictors of Biochemical Failure (multivariate analysis).
Gleason Score 0.03
PSA 0.41
T-Stage 0.4
PAP 0.001
beyond ﬁve years and 149 patients followed beyond 10
years (Figure 1). The overall freedom-from-failure for the
157 patients with intermediate risk disease was 89% while
the overall freedom-from-failure for the 164 patients having
high risk features was 74% at 16 years. It was most
encouragingtoﬁndthattheabsoluteriskoffailuredecreased
progressively with time, with only 1% of patients failing
beyond 6 years of completing treatment. Fifty-two patients
developedbiochemicalfailure.Ofthese52patients,27(51%)
failed within the ﬁrst three years after treatment. Follow-
up transperineal saturation prostate biopsies (minimum
25 cores) were performed on all failing patients, within 2
months of biochemical failure (MD). There were no patho-
logically documented local failures. None were characterized
as “indeterminate” (DB) nor was there clinical (DRE, new
onset of obstructive uropathy, pelvic pain) evidence of local
failure.
Of the 3 NCCN risk features (PSA, Gleason score, and
clinical stage)only pretreatment PSA and Gleason scorewere
eachassociatedwithahigherfailurerate(Table 2).Therewas
no statistical signiﬁcance between clinical stage (P = .4). The
strongest predictor of failure was Gleason score (P = .03)
(Figure 2)a n dP S A( P = .041) (Figure 3). Neoadjuvant and
adjunctive hormonal therapy did not aﬀect the failure rates
(P = .14, Figure 4). Consistent with this author’s (M.D.)
previous experience, PAP was identiﬁed to be the strongest
predictor of biochemical failure (P = .001).
Postimplant prostatic dosimetric evaluation was per-
formed on all patients demonstrating mean and median
V100’s to be 99.5 and 98.3, respectively, while mean and
median D90’s were 105 and 102, respectively.
Treatment morbidity was primarily limited to 3–6
months RTOG grade 1-2 urinary and rectal symptoms (80%
RTOG grade 1, 20% grade 2). These symptoms occurred
3–6 months following completion of treatment and all
spontaneously resolved with the exception of one patient
who developed RTOG grade 3 toxicity. This patient expe-
rienced chronic intermittent urinary obstruction symptoms
and had both a posttreatment TUIP and TURP resulting
in low volume stress incontinence. Fifteen patients required
immediate postimplant catheterization limited to 24–48
hours. None required indwelling catheterization beyond 48
hours and none required repeated self-catheterization. No
patient developed rectal ﬁstula or ulceration.
4. Discussion
The reintroduction of brachytherapy in the late 1980s
was met with tremendous skepticism and misconceptions
regarding which patients, if any, are best served with this
modality. Skepticism has since given way to widespread4 Journal of Oncology
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Figure 3: Freedom from biochemical progression (PSA <
0.2ng/mL, nadir +2) stratiﬁed per PSA elevation (multivariate
analysis).
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Figure 4: Freedom from biochemical progression (PSA <
0.2ng/mL, nadir +2) with or without adjuvant hormonal therapy
(univariate analyis).
acceptance of brachytherapy alone for patients with low
PSA and Gleason score [2]. However, there still remains
widespread perception that brachytherapy is not appro-
priate for patients at higher risk of ECE. A recent Euro-
pean consensus statement, for instance, recommended that
brachytherapy be limited to patients with low PSA and
Gleason scores [3]. On the contrary, this and other series
suggest that brachytherapy-based treatment may, in fact, be
a very desirable treatment modality for such patients when
performed in combination with EBRT. Brachytherapy, if
designed to deliver generous cancercidal margins around the
prostate given in addition to those with supplemental EBRT,
appears capable of eradicating both larger intraprostatic
tumormassesalongwithECE[22,23].Hormonesoﬀeredno
survival advantage (P = .14) in keeping with multiple other
brachytherapy studies using high dose radiation [6, 24–27].
This is in contrast to recent studies demonstrating survival
advantage using lower doses as is the case with full course
external beam irradiation and androgen blockade without
brachytherapy, including the Trans-Tasman randomized
control trial (median 6 months hormonal manipulation
[28, 29]) and other studies using a median of 2 years and
3y e a r s[ 30–32]. Because there is a large degree of overlap
in PSA, Gleason score and Clinical Stage between patients
with or without biochemical failure, even patients with
markedly elevated parameters appear to have a chance for
cure. Accordingly, our policy is to treat patients with curative
intent, even with markedly elevated parameters, provided a
bone scan and pelvic CT are negative for metastatic disease.
Recent data suggest that in those patients having high
risk malignancy, the disease is predominantly conﬁned
within the pelvis including the prostate and periprostatic
tissues, seminal vesicles, and pelvic lymph nodes [6, 33, 34].
Based on results obtained from our study published in
1996 which utilized preimplant external radiation followed
by brachytherapy, beginning in February 1997, we began
boosting periprostatic tissues and lymph nodes up to the
common iliacs to a much higher cancercidal dose level (60–
75Gy) while blocking the prostate plus a calculated margin
[35]. This method was applied to the ﬁnal 7 patients in this
study. This dose escalation boost has become more easily
accomplished with the advent of the more sophisticated
versions of IMRT.
Initial studies demonstrate favorable tumor control rates
with brachytherapy-based regimens were met with skepti-
cism due to short follow-up times. However, the increasing
number of studies with long-term follow-up uniformly
achieves results that compare favorably to those with surgery
or beam radiation alone. It is encouraging that the failure
rate decreased to <1% per year (90% of surviving patients
having PSA’s < .05 and the remainder having PSA’s of <.2)
with follow-up beyond 6 years with no pathological local
failures documented. While longer follow-up will always be
beneﬁcial, evidence from this patient group at higher risk
of extracapsular cancer extension and others suggest that
relatively high tumor control rates with brachytherapy-based
therapyarequitedurable[6,13,14,16].Thisincreasingbody
of evidence strengthens the rationale that brachytherapy-
based treatment is a very desirable treatment modality
for patients having intermediate and high risk disease,
although prospective studies will ultimately be necessary to
corroborate these positive results.
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